We determined the free fraction of 25-dihydroxyvitamin D (250HD) in the serum of subjects with clinical evidence of liver disease and correlated these measurements to the levels of vitamin D binding protein and albumin. These subjects when compared to normal individuals had lower total 250HD levels, higher percent free 250HD levels, but equivalent free 250HD levels.
Introduction
Patients with liver disease often present with low circulating levels of 25 -hydroxyvitamin D (250HD)' (1) (2) (3) . This metabolite of vitamin D is produced by the liver (4) , and its measurement is used to assess the vitamin D status ofthe patient. The correlation of250HD levels with various indices ofliver function (1) suggests that patients with liver disease have a compromised capacity to metabolize vitamin D to 250HD. Since patients with liver disease frequently have bone disease in association with low 250HD levels (5, 6) , various forms of vitamin D have been used as therapy for such patients (7) . However, osteoporosis, not osteomalacia (as would be expected in vitamin D-deficient states), is the predominant form ofbone disease in most patients with cirrhosis ( [8] [9] [10] [11] [12] , and in most studies (5, (9) (10) neither vitamin D nor 250HD therapy has been effective in treating this type of os- teoporosis. Furthermore, 250HD levels do not correlate well with the extent of osteomalacia (6) , and a deficiency in 250HD production by the cirrhotic liver has not been conclusively demonstrated (2, 11, 13) .
One explanation for low levels ofthe vitamin D metabolites in patients with liver disease without osteomalacia is that the carriers of the vitamin D metabolites in serum, vitamin D binding protein (DBP) and albumin ( [14] [15] [16] [17] , are also low. DBP and albumin are produced in the liver (18) , and the levels of both are reduced in the serum of patients with liver disease (19) . A reduction of DI3P and albumin concentrations would reduce the total concentration of the vitamin D metabolites without reducing the free or unbound concentrations. Therefore, if the free vitamin D metabolite concentrations are the physiologically important concentrations with respect to taiget tissue response, then total vitamin D metabolite measurements may not accurately indicate the vitamin D status ofpatients with liver disease.
We recently (20) adapted the technique of centrifugal ultrafiltration (21) to measure free 1,25-dihydtoxyvitamin D (1,25[OHJ2D) in serum and observed that patients with liver disease have normal free 1,25(OH)2D levels despite low total 1,25(OH)ID levels. In this report, we applied this method to the measurement of free 250HD levels. Our results indicate that patients with liver disease had low total 250HD levels that correlated with their low DBP and albumin levels, but most ofthese patients had normal free 250HD levels.
Methods
Subjects. Blood was obtained from 25 normal subjects aged 24-50 yr (13 males, 12 females) and 42 subjects aged 22-70 yr(34 males, 8 females) with clinical evidence ofliver disease. Three ofthe normal females were using oral contraceptives. Nearly all ofthe subjects with liver disease had a history of alcohol abuse; cirrhosis was documented by biopsy in 19.
Two of the subjects with liver disease were taking diphenylhydantoin, and one had been given oral supplements ofvitamin D before the blood sample was obtained. With these exceptions, the subjects were not taking drugs known to affect the vitamin D endocrine system. Excluding these subjects from the data analysis did not alter the conclusions. A history offractures associated with trauma was discovered in two ofthe subjects with liver disease.
Analyses. The free fraction of 250HD in serum for all ofthe subjects was determined using the following modification of centrifugal ultrafiltration originally developed by Hammohd et al. (21) . 450 levels were calculated as the product of the free fraction and total 250HD level. Equilibrium dialysis to measure the free fraction of 250HD was performed in Plexiglas units with chambers separated by the same dialysis tubing used for the centrifugal ultrafiltration vials. In this method, 1.6 ml of the diluted serum was incubated with 0.2 uCi freshly purified [3H]250HD3, and two 0.75-ml aliquots were dialyzed each against 2.6 ml PBS for up to 96 h at 370C. At the end of dialysis, aliquots from each side of the chamber were analyzed for 3H and the free fraction of 250HD was calculated as: [3H]b/[3H]s, where b = the buffer side and s = the serum sample side. After removal of the original buffer and sample, the units were washed with methanol to extract any [3H]250HD that adhered to the sides.
The free fraction of 250HD was also estimated using a commercially available ultrafiltration device (Centricon, Amicon Corp., Danvers, MA). The membrane of the unit was washed sequentially with 0.1 M NaOH, 70% ethanol, 10 mM NaHCO3, 2 mM EDTA, water, and PBS in a fashion similar to the washing of the dialysis membranes used for equilibrium dialysis and centrifugal ultrafiltration described above. Serum samples were prepared as for centrifugal ultrafiltration; 0.5-ml aliquots were added to the upper chamber of the Centricon apparatus and the samples were then centrifuged at 800 g for 10 min at 37°C. The entire ultrafiltrate (-50 Ml) and a 30-Ml aliquot of the sample were analyzed for 3H and`4C; the free fraction was calculated as for the results from centrifugal ultrafiltration described above.
Total 250HD levels in serum were determined in 54 of the subjects by the method of Eisman et al. DBP levels were measured in 52 of the subjects by rocket immunoelectrophoresis (23) using purified human DBP as standard and monospecific antiserum developed in rabbits. Albumin levels in 64 of the subjects, calcium levels in 51 of the subjects, phosphorus levels in 42 ofthe subjects, and creatinine levels in 38 of the subjects were measured by automated clinical laboratory techniques.
Statistical analyses used the statistical package SAS and employed these procedures: correlation, Student's t test, plot, and general linear models (for linear regression).
Results
In initial experiments, we compared the methods of centrifugal ultrafiltration and equilibrium dialysis. Equilibrium dialysis for 48 h resulted in free 250HD levels that were one-half to onethird that obtained by centrifugal ultrafiltration. However, we observed that when the free metabolite was dialyzed into the buffer solution across the membrane of the dialysis chamber, much of the metabolite adhered to the sides ofthe chamber and equilibrium was not achieved even after 96 h. Furthermore, the free metabolite decomposed during this time, and only a small fraction of the tracer was recovered as 25OHD from the buffer side of the dialysis chamber. In contrast, 85-100% of the tracer in the ultrafiltrate from centrifugal ultrafiltration was recovered as 250HD when rechromatographed with the HPLC system used in its purification.
We then compared results from our method of centrifugal ultrafiltration using two vials to those from the use of a commercially available ultrafiltration device. The free fraction of 250HD obtained using the commercially available device was one-third to one-tenth that obtained using the two-vial method. However, most ofthe 250HD that passed through the membrane of the commercial device bound to the plastic support underneath the membrane and was not recovered in the ultrafiltrate. The two-vial centrifugal ultrafiltration apparatus that we used to obtain the data for this report is constructed such that the dialysis membrane covering the one end of the inner vial rests directly on filter pads in the bottom of the outer collection vial. During at least 120 min of centrifugation, [3H]250HD appeared in the collection vial in parallel with the ['4C]glucose used to mark the free water of the ultrafiltrate, indicating that the [3H]25OHD is not being preferentially absorbed by the filter pads during the centrifugation. Therefore, we conclude that centrifugal ultrafiltration using the two-vial method accurately measured the free fraction of 250HD, whereas equilibrium dialysis and ultrafiltration using the commercially available apparatus underestimated this measurement.
The very low free fraction of 25OHD in serum (0.00030±0.00007 in normal individuals) prevents an accurate assessment in whole serum; therefore, the serum was diluted before the -assay was performed. Dilutions of serum from 1/30 to 1/300 with PBS gave equivalent results when corrected to whole serum. At higher dilutions (1/1000 and above), the high affinity binding site for 250HD in serum (DBP) began to be saturated with the concentration of [3H]25OHD in the sample (' 1.5 nM), and at such dilutions the apparent free 25OHD level was no longer linear with the dilution of the serum.
The pH of serum adjusted with 0, 5, or 10% C02 did not affect the measured free 25OHD level. Varying the incubation time of25OHD in serum from 5 to 60 min before centrifugation did not affect the measured free 25OHD level. Increasing the duration of centrifugation from 30 to 120 min did not affect the measured free 250HD level. In six consecutive assays, the intraand intercoefficients of variation were 9.5 and 8%, respectively.
The serum levels of calcium, phosphorus, and creatinine in normal subjects and in subjects with liver disease are shown in Table I . The serum calcium levels were lower in the subjects with liver disease (9.7±0.4 vs. 8.1±0.7 md/dl, P < 0.001). However, as Table II shows, the albumin levels in the subjects with liver disease were also reduced (4.46±0.24 vs. 2.83±0.66 g/dl). Serum calcium was highly correlated with serum albumin levels (r = 0.899, P < 0.001). Serum phosphorus and creatinine levels did not differ significantly between the two groups of subjects.
The serum levels of total 250HD, percent free 250HD, free 250HD, DBP, and albumin in normal subjects and subjects with liver disease are shown in Table II. In the serum of subjects with liver disease, the DBP was 44% ofnormal, the albumin was 59% of normal, and the total 250HD was 57% of normal. The percentage ofthe total 250HD that was free in the subjects with liver disease was 0.068 or 226% of normal. The free concentra- tions of 250HD (6.61±4.6 pg/ml) in these subjects were not significantly different from normal (5.88±2.27 pg/ml). The total 250HD was positively correlated to DBP (r = 0.571, P < 0.0001) and albumin (r = 0.562, P < 0.001) (Fig.  1) when data from both cirrhotic and normal subjects were combined. The correlations remained significant (r = 0.465, P < 0.02; r = 0.367, P < 0.05 for the correlations of 250HD to DBP and albumin, respectively) when data from the cirrhotic subjects were analyzed separately, but not when data from normal individuals were analyzed separately. The percent free 250HD was negatively correlated to DBP (r = 0.766, P < 0.0001) and albumin (r = 0.586, P < 0.0001) when data from both cirrhotic and normal subjects were combined, although the plot of percent free 250HD and DBP was not linear (Fig. 2) . At a DBP concentration above 300 Ag/ml, little further reduction in percent free 250HD was observed. The correlation of percent free 250HD to DBP remained significant when data from cirrhotic subjects were analyzed separately (r = 0.693, P < 0.0001); this correlation was not significant for the data from normal subjects, and the correlation for percent free 250HD to albumin was not significant for data from either group analyzed separately. Ahsul g/i whether the data from both groups of subjects were combined or separated (Fig. 3) . Neither the free 250HD nor the total 250HD correlated to serum calcium, phosphorus, or creatinine levels when the influence ofalbumin was factored out by multiple analysis of variance.
Discussion
The (-) and in 10 normal subjects (A), and the level of albumin (B) in 29 subjects with liver disease (A) and in 12 normal subjects (A). Only data from samples in which both measurements were made in the same sample are included.
eases (24) . Because 250HD is produced by the liver, the low 250HD levels associated with liver disease have been attributed to reduced production of 250HD by the diseased liver (25) . A number of studies have failed to demonstrate a significant loss of 250HD production in patients with liver disease (2, 11, 13) , however, and the correlation between the serum levels of250HD and osteomalacia in patients with liver disease is poor (7) . In this study, we found that the free concentration of 250HD in subjects with liver disease was normal, despite the low total concentration of 250HD. This result is consistent with our previous finding (20) (27) have calculated that 88% of the serum 250HD was bound to DBP in normal subjects, whereas this fell to 83% in patients with liver disease. (-10-9 M) . However, because of the excess of DBP and albumin even in the diluted samples (-5 X 10-1 M and -7 X 10-6 M, respectively), the additional amount of 250HD does not alter the fraction of 250HD bound to these proteins. In other experiments, we have not observed a change in the free fraction of 250HD until concentrations of 250HD in the sample approached those of the DBP concentrations.
This study reports the first directly measured free 250HD concentrations in human serum. Only 0.03% of total 250HD in serum was free in normal individuals. This percentage was increased in subjects with liver disease who had reduced DBP and albumin levels, a finding that is consistent with the role of DBP and albumin in transporting the vitamin D metabolites in blood. Because ofthe large excess capacity ofDBP and albumin for 250HD, in the absence ofa change in affinity ofthese proteins for 250HD, the percent free 250HD is reciprocally related to the DBP and albumin concentrations by the equilibrium constant of the binding reaction. The rise in percent free 250HD in the serum of subjects with liver disease compensated for the fall in total 250HD levels such that the free 250HD levels remained normal in most patients. This observation may account for part ofthe difficulty in correlating total 25OHD levels to the presence ofosteomalacia in subjects with liver disease. We believe that measurement of free 25OHD in subjects with liver disease will provide important additional information in assessing their vitamin D status.
